<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001506</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0116</org_study_id>
    <nct_id>NCT02001506</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer</brief_title>
  <acronym>Neo-shorter</acronym>
  <official_title>A Randomized Phase III Trial of Neoadjuvant Chemotherapy With 3 Cycles of FEC Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Adriamycin Plus Cyclophosphamide Followed by 4 Cycles of Docetaxel in Node-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various regimens and schedule as neoadjuvant chemotherapy regimens were investigated and
      sequential treatment of anthracyclines followed by taxanes, which has shown superior
      pathologic complete respone (pCR) rate (NSABP-B27 study) is widely used until now.
      Considering the proven efficacy and tolerable toxicity of 3 cycles of FEC followed by 3
      cycles of Docetaxel (FEC3-D3) compared to FEC 6 cycles in adjuvant chemotherapy (PACS 01
      trial), use of FEC3-D3 regimen in neoadjuvant setting will be feasible with acceptable
      efficacy and further reduce the duration of neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate feasibility of FEC3-D3 regimen in neoadjuvant setting in terms of comparable
      efficacy and shorter duration across all subtypes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response (pCR) between two arms</measure>
    <time_frame>within the first 30 days (plus or minus 3 days) after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year-disease free survival between two arms</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>Correlation of pCR and Ki-67 expression at baseline and D14 tumor specimen
3 year-disease free survival
Correlation of pCR and biomarkers such as Ki-67 expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FEC3-D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of FEC followed by 3 cycles of Docetaxel
Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
Docetaxel 75 mg/m2, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC4-D4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel
Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks
Docetaxel 75 mg/m2, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC3-D3</intervention_name>
    <description>Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
Docetaxel 75 mg/m2, every 3 weeks</description>
    <arm_group_label>FEC3-D3</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Pharmorubicin</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status 0 or 1

          -  Clinically stage 2 or 3 with histologically proven lymph node involvement

          -  Tumor or lymph node greater than 1.5 cm

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Prior chemotherapy or radiotherapy for any malignancy

          -  Documented history of cardiac disease contraindicating anthracyclines

          -  Currently active infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Bae Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>August 26, 2017</last_update_submitted>
  <last_update_submitted_qc>August 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Bae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>different number of chemotherapy cycles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

